<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785365</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-LTFU-001</org_study_id>
    <nct_id>NCT04785365</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Study of Patients Receiving ATL001</brief_title>
  <official_title>An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achilles Therapeutics UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achilles Therapeutics UK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and&#xD;
      clinical activity of ATL001, previously administered intravenously to patients in Study&#xD;
      ATX-NS-001 (NCT04032847) or Study ATX-ME-001 (NCT03997474).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 90 patients with advanced non-small cell lung cancer ( NSCLC) or melanoma will be&#xD;
      enrolled after either: completing 2 years of follow-up visits in study ATX-NS-001 or study&#xD;
      ATX-ME-001; or voluntary withdrawal from these studies prior to the completion of the 2 year&#xD;
      of follow-up period.&#xD;
&#xD;
      Each patient will be followed up for a minimum period of 5 years, or until death if sooner,&#xD;
      in this Long-Term Follow Up Protocol.&#xD;
&#xD;
      For patients who are still alive after 5 years of follow-up, survival data will continue to&#xD;
      be collected until the end of the study, which will occur when the last patient has completed&#xD;
      5 years of follow-up withdraws from study or has died.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events to evaluate Safety and Tolerability of ATL001</measure>
    <time_frame>Every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months.</time_frame>
    <description>Evaluate the frequency and severity of adverse events related to ATL001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of autoimmune adverse events</measure>
    <time_frame>Every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months.</time_frame>
    <description>Evaluate the frequency and severity of autoimmune adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of new malignancies</measure>
    <time_frame>Every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months.</time_frame>
    <description>Evaluate the frequency and severity of new malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Duration of Response ( DoR)</measure>
    <time_frame>Maximum 60 months.</time_frame>
    <description>Evaluate the endpoint of duration of response, as assessed by investigator and Independent Central Review (ICR) per Response Evaluation Criteria in Solid Tumors ( RECIST) version1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Progression Free Survival</measure>
    <time_frame>Maximum 60 months.</time_frame>
    <description>Evaluate the efficacy endpoint of progression-free survival ( PFS) as assessed by the investigator and ICR per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Time to first subsequent anti-cancer therapy</measure>
    <time_frame>Maximum 60 months.</time_frame>
    <description>Evaluate the long-term requirement for anti-cancer therapy after ATL001 therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months until death or until the end of the study, whichever came first, assessed up to 84 months.</time_frame>
    <description>Evaluate overall survival ( OS) by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Cancer-related medical resources</measure>
    <time_frame>Maximum 60 months.</time_frame>
    <description>Evaluate the long-term requirement for cancer-related medical resources following ATL001 therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Melanoma</condition>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Long-Term Follow-Up of Patients who Received ATL001</intervention_name>
    <description>Patients who received ATL001 in a clinical trial will be evaluated in this trial for long-term efficacy and safety.</description>
    <arm_group_label>Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have given written informed consent to participate in the study.&#xD;
&#xD;
          2. Patients must have received ATL001 in previous Clinical Trial ATX-NS-001 or&#xD;
             ATX-ME-001.&#xD;
&#xD;
          3. Patients must be considered, in the opinion of the Investigator, capable of complying&#xD;
             with the protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Achilles Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior VP Clinical Operations Achilles Therapeutics, PhD</last_name>
    <phone>+44 (0)208 154 4600</phone>
    <email>info@achillestx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ben Creelan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Enriqueta Felip, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Gary Middleton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Pippa Corrie, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gary Doherty, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Fiona Collison, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <zip>NW12PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Heather Shaw, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Forster, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie Papa, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>James Spicer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Samra Turajlic, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Fiona Thistlethwaite, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof Ruth Plummer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alastair Greystoke, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Ioannis Karydis, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Judith Cave, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04032847?term=achilles+therapeutics&amp;draw=2&amp;rank=1</url>
    <description>ATX-NS-001 Clinicaltrials.gov</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03997474?term=achilles+therapeutics&amp;draw=1&amp;rank=2</url>
    <description>ATX-ME-001 Clinicaltrials.gov</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

